Pfizer scientist wins Select Science award for oncology research video

The award reflects a broader shift in how pharmaceutical research balances technological innovation with fundamental scientific rigor. The Pfizer scientist's remarks underscore a critical tension in modern drug development: as AI and machine learning tools proliferate, the bottleneck is not computation but data quality. This insight has practical implications for companies like Shimadzu, whose analytical instrumentation (chromatography and SFC systems) remains essential to generating the high-quality datasets that train and validate AI models in drug discovery and development.

The 12–13 year partnership between Pfizer and Shimadzu, intensifying over the past five to six years, suggests that as pharma companies invest in AI-driven research pipelines, they simultaneously deepen investments in upstream analytical infrastructure. For oncology specifically—where cancer incidence and age of onset are both rising—this combination of rigorous data acquisition and computational acceleration may be critical to accelerating the discovery and validation of new treatments.